These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 29272392

  • 21. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Mira JA, García-Rey S, Rivero A, de los Santos-Gil I, López-Cortés LF, Girón-González JA, Téllez F, Márquez M, Merino D, Ríos-Villegas MJ, Macías J, Rivero-Juárez A, Pineda JA.
    Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
    [Abstract] [Full Text] [Related]

  • 22. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A, Polis M, Rozenberg L, Jackson J, Reitano K, McLaughlin M, Koratich C, Dewar R, Masur H, Haagmans B, Kottilil S.
    AIDS; 2007 Sep 12; 21(14):1855-65. PubMed ID: 17721093
    [Abstract] [Full Text] [Related]

  • 23. Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection.
    Anthony DD, Conry SJ, Medvik K, Sandhya Rani MR, Falck-Ytter Y, Blanton RE, Lederman MM, Rodriguez B, Landay AL, Sandberg JK.
    J Infect Dis; 2012 Sep 15; 206(6):969-73. PubMed ID: 22782948
    [Abstract] [Full Text] [Related]

  • 24. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
    Fernández-Montero JV, Barreiro P, Vispo E, Labarga P, Sánchez-Parra C, de Mendoza C, Treviño A, Soriano V.
    Antivir Ther; 2014 Sep 15; 19(3):287-92. PubMed ID: 24192598
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells.
    Marras F, Casabianca A, Bozzano F, Ascierto ML, Orlandi C, Di Biagio A, Pontali E, Dentone C, Orofino G, Nicolini L, Taramasso L, Magnani M, Marincola FM, Wang E, Moretta L, De Maria A.
    J Virol; 2017 Dec 01; 91(23):. PubMed ID: 28956765
    [Abstract] [Full Text] [Related]

  • 31. Liver cirrhosis in HIV/HCV-coinfected individuals is related to NK cell dysfunction and exhaustion, but not to an impaired NK cell modulation by CD4+ T-cells.
    Polo ML, Ghiglione YA, Salido JP, Urioste A, Poblete G, Sisto AE, Martinez A, Rolón MJ, Ojeda DS, Cahn PE, Turk GJ, Laufer NL.
    J Int AIDS Soc; 2019 Sep 01; 22(9):e25375. PubMed ID: 31536177
    [Abstract] [Full Text] [Related]

  • 32. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M, da Silva MH, Vilar FC, Seixas-Santos Nastri AC, Ferreira PA, Focaccia R, Mendes Correa MC.
    Ann Hepatol; 2013 Sep 01; 12(2):228-35. PubMed ID: 23396734
    [Abstract] [Full Text] [Related]

  • 33. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
    Mandorfer M, Neukam K, Rivero A, Puoti M, Boesecke C, Baumgarten A, Grzeszczuk A, Zangerle R, Ernst D, Rockstroh JK, Trauner M, Pineda JA, Peck-Radosavljevic M, Reiberger T.
    Antivir Ther; 2014 Sep 01; 19(4):407-14. PubMed ID: 24342953
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D, Rockstroh JK, Orkin C, Gutiérrez F, Klein MB, Reynes J, Shukla U, Jenkins A, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, De La Rosa G, Tambuyzer L, Jessner W.
    Clin Infect Dis; 2014 Dec 01; 59(11):1579-87. PubMed ID: 25192745
    [Abstract] [Full Text] [Related]

  • 40. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.
    Gonzalez VD, Falconer K, Blom KG, Reichard O, Mørn B, Laursen AL, Weis N, Alaeus A, Sandberg JK.
    J Virol; 2009 Nov 01; 83(21):11407-11. PubMed ID: 19710147
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.